Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma

12 Jul 2019

Abstract excerpt

Abstract Genome-wide CRISPR/Cas9 screens represent a powerful approach to studying mechanisms of drug action and resistance. Cereblon modulating agents (CMs) have recently emerged as candidates for therapeutic intervention in primary effusion lymphoma (PEL), a highly aggressive cancer caused by Kaposi’s sarcoma-associated herpesvirus. CMs bind to cereblon (CRBN), the substrate receptor of the cullin-RING type E3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31300418
DOI: 10.1182/bloodadvances.2019031732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphomaPMID 31300418Read ↗

Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion LymphomaSemantic proximity Read ↗

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myelomaSemantic proximity Read ↗

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapySemantic proximity Read ↗

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical ApplicationsSemantic proximity Read ↗

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read ↗

UBE2G1 Governs the Destruction of Cereblon Neomorphic SubstratesSemantic proximity Read ↗

Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphomaSemantic proximity Read ↗

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.Semantic proximity Read ↗

Integrated proteomic screening reveals design principles of CRBN molecular glue degradersSemantic proximity Read ↗

A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.Semantic proximity Read ↗

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.